# Limits the substitution of abuse-deterrent analgesic opioid drug products for analgesic opioids lacking such technology

**Bill ID:** S4754
**Session:** 2024
**Sponsor:** Andrew J. Lanza
**Status:** In Senate Committee
**PDF:** [S4754 PDF](https://legislation.nysenate.gov/pdf/bills/2024/S4754)

## Summary

Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.

---

## Full Text

S T A T E  O F  N E W  Y O R K
 ________________________________________________________________________
 
  4754
 
  2023-2024 Regular Sessions
 
  I N  S E N A T E
 
  February 14, 2023
  ___________
 
 Introduced  by  Sen.  LANZA  -- read twice and ordered printed, and when
  printed to be committed to the Committee on Insurance
 
 AN ACT to amend the insurance law, in relation to the use of  abuse-det-
  errent  technology  for  opioids as a mechanism for reducing abuse and
  diversion of opioid drugs

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
  Section 1. The insurance law is amended by adding a new section 3216-a
 to read as follows:
  ยง 3216-A.  ACCESS TO ABUSE-DETERRENT OPIOID MEDICATIONS. (A) AN INSUR-
 ANCE  CARRIER  OR  HEALTH  PLAN SHALL PROVIDE COVERAGE ON ITS FORMULARY,
 DRUG LIST OR OTHER LISTS OF SIMILAR CONSTRUCT FOR AT  LEAST  ONE  ABUSE-
 DETERRENT  OPIOID  ANALGESIC  DRUG  PRODUCT  PER OPIOID ANALGESIC ACTIVE
 INGREDIENT.
  (1) COST-SHARING FOR BRAND NAME ABUSE-DETERRENT OPIOID ANALGESIC  DRUG
 PRODUCTS  COVERED  PURSUANT  TO THIS SECTION SHALL NOT EXCEED THE LOWEST
 COST-SHARING LEVEL APPLIED TO  BRAND  NAME  NON-ABUSE  DETERRENT  OPIOID
 DRUGS COVERED UNDER THE APPLICABLE HEALTH PLAN OR POLICY.
  (2)  COST-SHARING  FOR  GENERIC  ABUSE-DETERRENT OPIOID ANALGESIC DRUG
 PRODUCTS COVERED PURSUANT TO THIS SECTION SHALL NOT  EXCEED  THE  LOWEST
 COST-SHARING  LEVEL  APPLIED TO GENERIC NON-ABUSE DETERRENT OPIOID DRUGS
 COVERED UNDER THE APPLICABLE HEALTH PLAN OR POLICY.
  (3) AN INCREASE IN PATIENT COST-SHARING OR DISINCENTIVES FOR  PRESCRI-
 BERS  OR DISPENSERS SHALL NOT BE ALLOWED TO ACHIEVE COMPLIANCE WITH THIS
 SECTION.
  (B) ANY PRIOR-AUTHORIZATION REQUIREMENTS OR OTHER  UTILIZATION  REVIEW
 MEASURES  FOR  OPIOID  ANALGESICS, AND ANY SERVICE DENIALS MADE PURSUANT
 THERETO, SHALL NOT REQUIRE USE OF OPIOID ANALGESIC DRUG PRODUCTS WITHOUT
 ABUSE-DETERRENT PROPERTIES IN ORDER  TO  ACCESS  ABUSE-DETERRENT  OPIOID
 ANALGESIC DRUG PRODUCTS.
  (C) DEFINITIONS. AS USED IN THIS SECTION:
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
  [ ] is old law to be omitted.
  LBD08756-01-3
 S. 4754  2
 
  (1)  "OPIOID  ANALGESIC DRUG PRODUCT" MEANS A DRUG IN THE OPIOID ANAL-
 GESIC DRUG CLASS PRESCRIBED TO TREAT MODERATE TO SEVERE  PAIN  OR  OTHER
 CONDITIONS, WHETHER IN IMMEDIATE RELEASE OR EXTENDED LONG ACTING RELEASE
 FORM  AND  WHETHER  OR NOT COMBINED WITH OTHER DRUG SUBSTANCES TO FORM A
 SINGLE DRUG PRODUCT OR OTHER DOSAGE FORM.
  (2)  "ABUSE  DETERRENT OPIOID ANALGESIC DRUG PRODUCT" MEANS A BRAND OR
 GENERIC OPIOID ANALGESIC DRUG PRODUCT APPROVED BY THE FEDERAL  FOOD  AND
 DRUG ADMINISTRATION WITH ABUSE-DETERRENCE LABELING CLAIMS INDICATING ITS
 ABUSE-DETERRENT PROPERTIES ARE EXPECTED TO DETER OR REDUCE ITS ABUSE.
  (3)  "COST-SHARING"  MEANS ANY COVERAGE LIMIT, COPAYMENT, COINSURANCE,
 DEDUCTIBLE OR OTHER OUT-OF-POCKET PATIENT EXPENSE REQUIREMENTS.
  ยง 2. This act shall take effect on the one hundred twentieth day after
 it shall have become  a  law,  and  shall  apply  to  all  policies  and
 contracts issued, renewed, modified, altered or amended on or after such
 date.